Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ALX Oncology Holdings Inc. - Common Stock
(NQ:
ALXO
)
2.040
+0.250 (+13.97%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
14,472,422
Open
1.790
Bid (Size)
2.000 (200)
Ask (Size)
2.040 (200)
Prev. Close
1.790
Today's Range
1.765 - 2.130
52wk Range
0.4040 - 2.660
Shares Outstanding
40,869,135
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ALX Oncology Targets Key Readouts to Advance CD47, EGFR Cancer Drug Programs
↗
June 03, 2026
ALX Oncology (NASDAQ:ALXO) executives said the company is focused on advancing two clinical-stage oncology programs, with upcoming data readouts expected to shape potential later-stage development...
Via
MarketBeat
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
↗
June 01, 2026
ALX Oncology (ALXO) Q1 2026 Earnings Transcript
Via
The Motley Fool
Performance
YTD
+77.4%
+77.4%
1 Month
+7.9%
+7.9%
3 Month
+6.8%
+6.8%
6 Month
+61.9%
+61.9%
1 Year
+402.7%
+402.7%
More News
Read More
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
June 01, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Holdings Inc (NASDAQ:ALXO) Beats Q1 Estimates and Unveils Promising Breast Cancer Data
↗
May 08, 2026
Via
Chartmill
ALX Oncology (NASDAQ:ALXO) Extends Cash Runway to 2028, Refines Evorpacept Strategy After Q4 Earnings
↗
February 27, 2026
Via
Chartmill
ALX Oncology Q1 Earnings Call Highlights
↗
May 08, 2026
Via
MarketBeat
Topics
Earnings
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 08, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology’s Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression
May 07, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
April 30, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
April 13, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology (ALXO) Q4 2025 Earnings Transcript
↗
February 27, 2026
Via
The Motley Fool
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 27, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
February 19, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
February 19, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Pricing of Underwritten Offering
January 30, 2026
From
ALX Oncology
Via
GlobeNewswire
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
January 30, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 08, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
January 08, 2026
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
December 07, 2025
From
ALX Oncology
Via
GlobeNewswire
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
Via
FinancialNewsMedia
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
November 19, 2025
From
FN Media Group LLC
Via
GlobeNewswire
ALX Oncology to Present at Upcoming Investor Conferences
November 18, 2025
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Holdings Inc (NASDAQ:ALXO) Reports Wider-Than-Expected Q3 2025 Loss Amid Promising Clinical Data
↗
November 07, 2025
Via
Chartmill
ALX Oncology Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 07, 2025
From
ALX Oncology
Via
GlobeNewswire
Earnings Scheduled For November 7, 2025
↗
November 07, 2025
Via
Benzinga
Frequently Asked Questions
Is ALX Oncology Holdings Inc. - Common Stock publicly traded?
Yes, ALX Oncology Holdings Inc. - Common Stock is publicly traded.
What exchange does ALX Oncology Holdings Inc. - Common Stock trade on?
ALX Oncology Holdings Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ALX Oncology Holdings Inc. - Common Stock?
The ticker symbol for ALX Oncology Holdings Inc. - Common Stock is ALXO on the Nasdaq Stock Market
What is the current price of ALX Oncology Holdings Inc. - Common Stock?
The current price of ALX Oncology Holdings Inc. - Common Stock is 2.040
When was ALX Oncology Holdings Inc. - Common Stock last traded?
The last trade of ALX Oncology Holdings Inc. - Common Stock was at 06/26/26 04:00 PM ET
What is the market capitalization of ALX Oncology Holdings Inc. - Common Stock?
The market capitalization of ALX Oncology Holdings Inc. - Common Stock is 83.37M
How many shares of ALX Oncology Holdings Inc. - Common Stock are outstanding?
ALX Oncology Holdings Inc. - Common Stock has 83M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
